Standout Papers

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial 2025 202632
  1. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial (2025)
    Armin Ghobadi, Veronika Bachanová et al. The Lancet

Immediate Impact

1 by Nobel laureates 12 from Science/Nature 52 standout
Sub-graph 1 of 22

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Natural killer cell therapies
2024 StandoutNature
3 intermediate papers

Works of Carlos Bachier being referenced

A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)
2020
Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.
2020
and 1 more

Author Peers

Author Last Decade Papers Cites
Carlos Bachier 620 440 370 86 1.4k
Amparo Sempere 378 399 266 64 1.4k
DC Linch 415 504 242 50 1.2k
Hyeon‐Seok Eom 836 515 416 132 1.7k
Chi Young Ok 569 664 232 85 1.5k
Kaaren K. Reichard 400 498 431 116 1.7k
Judit Demeter 407 415 262 107 1.5k
Paul G. Schlegel 586 480 473 56 1.7k
Adrian Bloor 470 431 303 63 1.4k
Carlos Panizo 440 281 266 91 1.4k
Maurizio Musso 354 672 268 66 1.3k

All Works

Loading papers...

Rankless by CCL
2026